• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » GE Healthcare lands FDA approval for new Alzheimer’s disease imaging agent

GE Healthcare lands FDA approval for new Alzheimer’s disease imaging agent

October 28, 2013 By Arezu Sarvestani

GE Healthcare lands FDA approval for new Alzheimer's disease imaging agent

FDA officials this month announced that the agency approved GE Healthcare’s (NYSE:GE) Vizamyl radiopharmaceutical for use in combination with PET imaging to help diagnose patients with Alzheimer’s disease and dementia.

Vizamyl is only the 2nd drug with FDA indication to help detect abnormal build-up of beta amyloid proteins in the brain, and the 1st with indication for visual interpretation of colored images, rather than only black and white.

Excess concentrations of beta amyloid protein in the brain is a key diagnostic feature of Alzheimer’s disease, causing impaired cognitive functions such as diminishing motor skills, memory, judgment and other symptoms.

"Many Americans are evaluated every year to determine the cause of diminishing neurologic functions, such as memory and judgment, that raise the possibility of Alzheimer’s disease," FDA Center for Drug Evaluation & Research deputy director Dr. Shaw Chen said in prepared remarks. "Imaging drugs like Vizamyl provide physicians with important tools to help evaluate patients for AD and dementia."

The FDA win was based on a pair of clinical trials with 761 total patient participants, which demonstrated that the "Vizamyl correctly detects beta amyloid in the brain," and that the scans produced with Vizamyl are reproducible and translatable by trained readers, according to the FDA notice.

GE Healthcare expects next year to begin commercially offering color-image PET imaging with Vizamyl, according to a company statement.

The only other imaging agency with FDA approval for the detection of beta amyloids in diagnosis of Alzheimer’s is Eli Lilly’s (NYSE:LLY) Amyvid, which won FDA approval last year and has since struggled to get wider reimbursement from the Centers for Medicare & Medicaid Services.

Filed Under: Food & Drug Administration (FDA), Imaging, Neurological, News Well, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: Alzheimer's disease, GE Healthcare

More recent news

  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy